Abstract 170P
Background
INFINITY captured RW profile and Tx strategies (chemotherapy-CT, immunotherapy-IO, radiotherapy-RT) of pts with ES NSCLC (IA-IIIC) in Greece, offering insights on inclusion of novel therapies in the clinic.
Methods
Nationwide, retrospective chart reviewstudy of 300 ES NSCLC pts diagnosed from 1/1/2016–31/12/2020 (index period) across st I/II/III (1:1:1), excluding pts in clinical trials. Observation period was from initial NSCLC diagnosis until occurrence of distant metastasis, informed consent obtention or death.
Results
Data from 300 pts were retrospectively abstracted in 16 centers from 13/10/2021 to 23/5/2022 (data cut off) accounting for 8.2% of ES NSCLC diagnoses at participating sites during index period. At inclusion, 41% of pts had progressed to higher NSCLC st and 38% were deceased. The table shows basic clinicopathologic characteristics. All but 3 pts received any Tx; 75% had surgical resection (93%, 90%, 41% of pts in st I, II, III, respectively), 74% received systemic treatment (ST) (38%, 85% and 98% of pts in st I, II, III, respectively) comprised mainly of CT (91%), and 29% had RT (in 10%, 14%, 61% of pts in st I, II, III, respectively). Overall, 68% of pts were managed with combined modality therapy. Among st III pts Tx patterns were highly variable; 42% had definitive CT-RT without surgery, whereas among resected pts, 71% received adjuvant ST, 20% neoadjuvant, and 5% both. Overall, 46% of all pts had biomarker testing: 33% for PD-L1 (70% PD-L1≥1%), 31% EGFR (16% pos), 28% ALK (2% pos), 16% BRAF (10% pos) and 13% KRAS (32% pos).
Table 170P| Initial diagnosis stage | ||||
| Overall N=300 | 1 N=100 | 11 N=100 | 111 N=100 | |
| Alive at study inclusion, % | 62.0 | 81.0 | 62.0 | 43.0 |
| Length of observation (months), median (IQR) | 23.9 | 26.8 | 24.3 | 18.8 |
| (15.6–36.8) | (18.1–39.7) | (15.6–37.2) | (10.0–31.1) | |
| Age (years), median | 67.4 | 68.1 | 66.3 | 68.0 |
| (IQR) | (61.7–73.0) | (61.2–73.0) | (61.6–72.9) | (62.5–74.1) |
| Male, % | 74.0 | 71.0 | 72.0 | 79.0 |
| Ever smokers, % | 89.4 | 84.4 | 88.2 | 95.6 |
| Body Mass Index (kg/m2), median (IQR) | 26.0 (23.5–28.4) | 26.6 (24.4–28.9) | 26.2 (23.3–28.0) | 25.6 (22.7–28.3) |
| Eastern Cooperative | 96.0 | 95.4 | 96.3 | 96.2 |
| Oncology Group | ||||
| Performance Status | ||||
ConclusionsCombined modality therapy is required in about 3/4 of ES-NSCLC pts. Less than 20% st III pts receive neoadjuvant systemic Tx. Biomarker testing rates in ES NSCLC are low. In view of the fast-evolving treatment landscape in ES NSCLC, above data are essential to support informed healthcare decision making. Editorial acknowledgementThe authors wish to thank Qualitis SA, a member of Optimapharm, for their medical writing and editorial support provided as part of the project work performed for MSD Greece. Legal entity responsible for the studyMSD Greece, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. FundingMSD Greece, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. DisclosureG. Mountzios: Financial Interests, Personal, Advisory Board: Roche, BMS, Takeda, Janssen, Sanofi; Financial Interests, Personal, Invited Speaker: MSD, AstraZeneca, Pfizer, Novartis, Amgen, AstraZeneca, Roche, Novartis, AstraZeneca, Lilly, GSK, Amgen, Gilead Pharmaceuticals, BMS; Financial Interests, Institutional, Invited Speaker: MSD. A. Koumarianou: Financial Interests, Personal, Invited Speaker: MSD, BMS, AstraZeneca, Servier; Financial Interests, Personal, Research Grant: Genfleet, Incyte, OBT, Merck, Roche. I. Boukovinas: Financial Interests, Personal, Research Grant: MSD, BMS, Novartis, Roche, Regeneron, Amgen, AstraZeneca, Boehringer Ingelheim, Genesis, Lilly; Financial Interests, Personal, Advisory Board: MSD, BMS, Novartis, Roche, Amgen, AstraZeneca, Boehringer Ingelheim, LEO, Galenica, Genesis, Sanofi, Ipsen, Gilead; Financial Interests, Personal, Invited Speaker: MSD, BMS, Novartis, Roche, Amgen, AstraZeneca, Boehringer Ingelheim, LEO, Galenica, Genesis, Sanofi, Ipsen, Gilead. H. Linardou: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, MSD, Merck, Takeda, Bristol Myers Squibb, Lilly, Pfizer, GSK, Sandoz; Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, MSD, Bristol Myers Squibb, Pfizer, Amgen, Novartis; Financial Interests, Personal, Stocks/Shares: BioPath Innovations S.A.; Financial Interests, Personal and Institutional, Invited Speaker: Bristol Myers Squibb, Boehringer Ingelheim, Roche, AbbVie, Lilly, Novartis, AstraZeneca, Amgen, PPD, Parexel ILR, Qualitis, Health Data Specialist; Financial Interests, Institutional, Invited Speaker: GSK; Non-Financial Interests, Personal, Principal Investigator: Hellenic Cooperative Oncology Group; Non-Financial Interests, Personal, Leadership Role, Elected Chair of the Scientific Committee: Hellenic Cooperative Oncology Group; Non-Financial Interests, Personal, Member of Board of Directors: Women 4 Oncology - Hellas, Fairlife Lung Cancer Care, Hellenic Cooperative Oncology Group, Hellenic Foundation for Cancer Research. A. Desiniotis: Financial Interests, Personal, Officer: MSD Greece. I. Dimitriadis: Financial Interests, Personal, Officer: MSD. E. Iliopoulou: Other, Personal, Officer: MSD Greece. All other authors have declared no conflicts of interest. This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
| ||||